ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

NAPROSYN SUSPENSION
Arthritis/rheumatic disorders
Dysmenorrhea
Nonnarcotic analgesics
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

NAPROSYN SUSPENSION Rx

Generic Name and Formulations:
Naproxen 125mg/5mL; pineapple-orange flavor.

Company:
Roche Laboratories

Therapeutic Use:

Indications for NAPROSYN SUSPENSION:

Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Juvenile rheumatoid arthritis (JRA). Tendinitis. Bursitis. Acute gout.

Adult:

Arthritis, spondylitis: 250–500mg twice daily; max 1.5g/day (up to 6 months). Tendinitis, bursitis: 500mg once, then 500mg twice daily or 250mg every 6–8 hrs; max (first day) 1.25g, then max 1g/day. Acute gout: 750mg once, then 250mg every 8 hrs.

Children:

<2yrs: not recommended. ≥2yrs: JRA: 5mg/kg twice daily. Other uses: Doses of 2.5–5mg/kg/dose, max 15mg/kg/day have been used.

See Also:

EC-NAPROSYN

NAPROSYN

Contraindications:

Aspirin allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events, MI, and stroke. Increased risk of serious GI adverse events (eg, bleeding, ulceration, perforation). Advanced renal disease: not recommended. Active peptic ulcer. History of GI or inflammatory bowel disease. Impaired renal or hepatic function. Hypovolemia. Heart failure. Salt depletion. Edema. Hypertension. Preexisting asthma. Bleeding disorders. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.

Interactions:

Avoid concomitant aspirin. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas). Monitor oral anticoagulants. Increased risk of GI bleeding with oral corticosteroids, SSRIs, smoking, alcohol. May antagonize diuretics, β-blockers, ACEIs, ARBs or other antihypertensives. Increased renal toxicity with ACEIs or ARBs. Methotrexate excretion reduced. Increases serum lithium levels. Probenecid increases plasma levels and delays elimination. Concomitant H2 blockers, sucralfate, intensive antacid therapy: use immediate-release forms of naproxen. Cholestyramine may delay absorption.

Adverse Reactions:

GI bleeding, peptic ulcer, constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, pruritus, rash (discontinue if occurs), tinnitus, edema, nephritis, nephrotic syndrome, jaundice, hepatitis. See full labeling re: risk of cardiovascular or GI events.

How Supplied:

Tabs—100; Susp—pt; EC—100

Indications for NAPROSYN SUSPENSION:

Dysmenorrhea.

Adult:

Initially 500mg, then 500mg every 12 hrs or 250mg every 6–8 hrs; max 1.25g (first day), then max 1g/day.

Children:

Not applicable.

See Also:

NAPROSYN

Contraindications:

Aspirin allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events, MI, and stroke. Increased risk of serious GI adverse events (eg, bleeding, ulceration, perforation). Advanced renal disease: not recommended. Active peptic ulcer. History of GI or inflammatory bowel disease. Impaired renal or hepatic function. Hypovolemia. Heart failure. Salt depletion. Edema. Hypertension. Preexisting asthma. Bleeding disorders. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.

Interactions:

Avoid concomitant aspirin. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas). Monitor oral anticoagulants. Increased risk of GI bleeding with oral corticosteroids, SSRIs, smoking, alcohol. May antagonize diuretics, β-blockers, ACEIs, ARBs or other antihypertensives. Increased renal toxicity with ACEIs or ARBs. Methotrexate excretion reduced. Increases serum lithium levels. Probenecid increases plasma levels and delays elimination. Concomitant H2 blockers, sucralfate, intensive antacid therapy: use immediate-release forms of naproxen. Cholestyramine may delay absorption.

Adverse Reactions:

GI bleeding, peptic ulcer, constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, pruritus, rash (discontinue if occurs), tinnitus, edema, nephritis, nephrotic syndrome, jaundice, hepatitis. See full labeling re: risk of cardiovascular or GI events.

How Supplied:

Tabs—100; Susp—pt

Indications for NAPROSYN SUSPENSION:

Mild to moderate pain.

Adult:

Initially 500mg, then 500mg every 12 hrs or 250mg every 6–8 hrs; max 1.25g (first day), then max 1g/day.

Children:

<2yrs: not recommended. ≥2yrs: use susp forms of naproxen.

See Also:

NAPROSYN

Contraindications:

Aspirin allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events, MI, and stroke. Increased risk of serious GI adverse events (eg, bleeding, ulceration, perforation). Advanced renal disease: not recommended. Active peptic ulcer. History of GI or inflammatory bowel disease. Impaired renal or hepatic function. Hypovolemia. Heart failure. Salt depletion. Edema. Hypertension. Preexisting asthma. Bleeding disorders. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.

Interactions:

Avoid concomitant aspirin. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas). Monitor oral anticoagulants. Increased risk of GI bleeding with oral corticosteroids, SSRIs, smoking, alcohol. May antagonize diuretics, β-blockers, ACEIs, ARBs or other antihypertensives. Increased renal toxicity with ACEIs or ARBs. Methotrexate excretion reduced. Increases serum lithium levels. Probenecid increases plasma levels and delays elimination. Concomitant H2 blockers, sucralfate, intensive antacid therapy: use immediate-release forms of naproxen. Cholestyramine may delay absorption.

Adverse Reactions:

GI bleeding, peptic ulcer, constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, pruritus, rash (discontinue if occurs), tinnitus, edema, nephritis, nephrotic syndrome, jaundice, hepatitis. See full labeling re: risk of cardiovascular or GI events.

How Supplied:

Tabs—100; Susp—pt

Sign Up for Free e-newsletters